Workflow
Leap Therapeutics Reports Second Quarter 2025 Financial Results

Selected Second Quarter 2025 Financial Results Net Loss was 16.6millionforthesecondquarter2025,comparedto16.6 million for the second quarter 2025, compared to 20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force. Research and development expenses were 10.5millionforthesecondquarterof2025,comparedto10.5 million for the second quarter of 2025, compared to 17.9 million for the same period in 2024. The decrease of $7. ...